Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity

Arunika Mukhopadhaya, Joseph Mendecki, Xinyuan Dong, Laibin Liu, Shalom Kalnicki, Madhur K. Garg, Alan Alfieri, Chandan Guha

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Prostate adenocarcinoma, treated with localized tumor hyperthermia (LTH), can potentially serve as a source of tumor antigen, where dying apoptotic/necrotic cells release tumor peptides slowly over time. In addition, LTH-treated cells can release heat shock proteins that can chaperone antigenic peptides to antigen-presenting cells, such as dendritic cells. We attempted to discern whether sequential LTH and intratumoral dendritic cell and/or systemic granulocyte macrophage colony-stimulating factor (GM-CSF) would activate antitumor immune response in a syngeneic murine model of prostate cancer (RM-1). Palpable RM-1 tumors, grown in the distal appendage of C57BL/6 male mice, were subjected to LTH (43.7°C for 1 h) x 2, separated by 5 days. Following the second LTH treatment, animals received either PBS or dendritic cells (2 × 106) intratumorally (every 3 days for three injections). Separate cohorts also received i.v. injection of recombinant adenovirus-expressing murine GM-CSF (AdGMCSF), 1 day after LTH. Control animals received AdenoLacZ or AdenoGFP. Intratumoral dendritic cell injection induced tumor-specific T-helper cell activity (IFNγ ELISPOTS) and CTL activity, which was further augmented by AdGMCSF, indicating amplification of tumor-specific TH1 immunity. The combination of LTH, AdGMCSF, and intratumoral dendritic cell injection resulted in significant tumor growth delays when compared with animal cohorts that received LTH alone. These results support an in situ autovaccination strategy where systemic administration of GM-CSF and/or intratumoral injection of autologous dendritic cells, when combined with LTH, could be an effective treatment for local and systemic recurrence of prostate cancer.

Original languageEnglish (US)
Pages (from-to)7798-7806
Number of pages9
JournalCancer Research
Volume67
Issue number16
DOIs
StatePublished - Aug 15 2007

Fingerprint

Dendritic Cells
Immunity
Fever
Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Injections
Adenoviridae
Prostatic Neoplasms
Peptides
Macrophage Colony-Stimulating Factor
Neoplasm Antigens
Antigen-Presenting Cells
Heat-Shock Proteins
Helper-Inducer T-Lymphocytes
Prostate
Adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. / Mukhopadhaya, Arunika; Mendecki, Joseph; Dong, Xinyuan; Liu, Laibin; Kalnicki, Shalom; Garg, Madhur K.; Alfieri, Alan; Guha, Chandan.

In: Cancer Research, Vol. 67, No. 16, 15.08.2007, p. 7798-7806.

Research output: Contribution to journalArticle

Mukhopadhaya, Arunika ; Mendecki, Joseph ; Dong, Xinyuan ; Liu, Laibin ; Kalnicki, Shalom ; Garg, Madhur K. ; Alfieri, Alan ; Guha, Chandan. / Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. In: Cancer Research. 2007 ; Vol. 67, No. 16. pp. 7798-7806.
@article{1dd906ec5d624d3485561a89b1ecc6b6,
title = "Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity",
abstract = "Prostate adenocarcinoma, treated with localized tumor hyperthermia (LTH), can potentially serve as a source of tumor antigen, where dying apoptotic/necrotic cells release tumor peptides slowly over time. In addition, LTH-treated cells can release heat shock proteins that can chaperone antigenic peptides to antigen-presenting cells, such as dendritic cells. We attempted to discern whether sequential LTH and intratumoral dendritic cell and/or systemic granulocyte macrophage colony-stimulating factor (GM-CSF) would activate antitumor immune response in a syngeneic murine model of prostate cancer (RM-1). Palpable RM-1 tumors, grown in the distal appendage of C57BL/6 male mice, were subjected to LTH (43.7°C for 1 h) x 2, separated by 5 days. Following the second LTH treatment, animals received either PBS or dendritic cells (2 × 106) intratumorally (every 3 days for three injections). Separate cohorts also received i.v. injection of recombinant adenovirus-expressing murine GM-CSF (AdGMCSF), 1 day after LTH. Control animals received AdenoLacZ or AdenoGFP. Intratumoral dendritic cell injection induced tumor-specific T-helper cell activity (IFNγ ELISPOTS) and CTL activity, which was further augmented by AdGMCSF, indicating amplification of tumor-specific TH1 immunity. The combination of LTH, AdGMCSF, and intratumoral dendritic cell injection resulted in significant tumor growth delays when compared with animal cohorts that received LTH alone. These results support an in situ autovaccination strategy where systemic administration of GM-CSF and/or intratumoral injection of autologous dendritic cells, when combined with LTH, could be an effective treatment for local and systemic recurrence of prostate cancer.",
author = "Arunika Mukhopadhaya and Joseph Mendecki and Xinyuan Dong and Laibin Liu and Shalom Kalnicki and Garg, {Madhur K.} and Alan Alfieri and Chandan Guha",
year = "2007",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-07-0203",
language = "English (US)",
volume = "67",
pages = "7798--7806",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity

AU - Mukhopadhaya, Arunika

AU - Mendecki, Joseph

AU - Dong, Xinyuan

AU - Liu, Laibin

AU - Kalnicki, Shalom

AU - Garg, Madhur K.

AU - Alfieri, Alan

AU - Guha, Chandan

PY - 2007/8/15

Y1 - 2007/8/15

N2 - Prostate adenocarcinoma, treated with localized tumor hyperthermia (LTH), can potentially serve as a source of tumor antigen, where dying apoptotic/necrotic cells release tumor peptides slowly over time. In addition, LTH-treated cells can release heat shock proteins that can chaperone antigenic peptides to antigen-presenting cells, such as dendritic cells. We attempted to discern whether sequential LTH and intratumoral dendritic cell and/or systemic granulocyte macrophage colony-stimulating factor (GM-CSF) would activate antitumor immune response in a syngeneic murine model of prostate cancer (RM-1). Palpable RM-1 tumors, grown in the distal appendage of C57BL/6 male mice, were subjected to LTH (43.7°C for 1 h) x 2, separated by 5 days. Following the second LTH treatment, animals received either PBS or dendritic cells (2 × 106) intratumorally (every 3 days for three injections). Separate cohorts also received i.v. injection of recombinant adenovirus-expressing murine GM-CSF (AdGMCSF), 1 day after LTH. Control animals received AdenoLacZ or AdenoGFP. Intratumoral dendritic cell injection induced tumor-specific T-helper cell activity (IFNγ ELISPOTS) and CTL activity, which was further augmented by AdGMCSF, indicating amplification of tumor-specific TH1 immunity. The combination of LTH, AdGMCSF, and intratumoral dendritic cell injection resulted in significant tumor growth delays when compared with animal cohorts that received LTH alone. These results support an in situ autovaccination strategy where systemic administration of GM-CSF and/or intratumoral injection of autologous dendritic cells, when combined with LTH, could be an effective treatment for local and systemic recurrence of prostate cancer.

AB - Prostate adenocarcinoma, treated with localized tumor hyperthermia (LTH), can potentially serve as a source of tumor antigen, where dying apoptotic/necrotic cells release tumor peptides slowly over time. In addition, LTH-treated cells can release heat shock proteins that can chaperone antigenic peptides to antigen-presenting cells, such as dendritic cells. We attempted to discern whether sequential LTH and intratumoral dendritic cell and/or systemic granulocyte macrophage colony-stimulating factor (GM-CSF) would activate antitumor immune response in a syngeneic murine model of prostate cancer (RM-1). Palpable RM-1 tumors, grown in the distal appendage of C57BL/6 male mice, were subjected to LTH (43.7°C for 1 h) x 2, separated by 5 days. Following the second LTH treatment, animals received either PBS or dendritic cells (2 × 106) intratumorally (every 3 days for three injections). Separate cohorts also received i.v. injection of recombinant adenovirus-expressing murine GM-CSF (AdGMCSF), 1 day after LTH. Control animals received AdenoLacZ or AdenoGFP. Intratumoral dendritic cell injection induced tumor-specific T-helper cell activity (IFNγ ELISPOTS) and CTL activity, which was further augmented by AdGMCSF, indicating amplification of tumor-specific TH1 immunity. The combination of LTH, AdGMCSF, and intratumoral dendritic cell injection resulted in significant tumor growth delays when compared with animal cohorts that received LTH alone. These results support an in situ autovaccination strategy where systemic administration of GM-CSF and/or intratumoral injection of autologous dendritic cells, when combined with LTH, could be an effective treatment for local and systemic recurrence of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=34548012362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548012362&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-0203

DO - 10.1158/0008-5472.CAN-07-0203

M3 - Article

C2 - 17699785

AN - SCOPUS:34548012362

VL - 67

SP - 7798

EP - 7806

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 16

ER -